Skip to main content
TSE:GUD

Knight Therapeutics Competitors

C$5.35
+0.10 (+1.90 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
C$5.28
C$5.40
50-Day Range
C$4.99
C$5.60
52-Week Range
C$4.88
C$7.71
Volume397,468 shs
Average Volume361,269 shs
Market CapitalizationC$688.89 million
P/E Ratio16.77
Dividend YieldN/A
BetaN/A

Competitors

Knight Therapeutics (TSE:GUD) Vs. LEAF, ACB, HEXO, OGI, HLS, and ICC

Should you be buying GUD stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Knight Therapeutics, including Leaf Mobile (LEAF), Aurora Cannabis (ACB), HEXO (HEXO), OrganiGram (OGI), HLS Therapeutics (HLS), and ICC Labs (ICC).

Knight Therapeutics (TSE:GUD) and Leaf Mobile (TSE:LEAF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Valuation & Earnings

This table compares Knight Therapeutics and Leaf Mobile's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$199.52 million3.45C$41.08 millionC$0.3216.77
Leaf MobileC$31.09 million10.57C$-17,580,671.00C($0.02)-18.70

Knight Therapeutics has higher revenue and earnings than Leaf Mobile. Leaf Mobile is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Knight Therapeutics and Leaf Mobile's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Knight TherapeuticsN/AN/AN/A
Leaf MobileN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Knight Therapeutics and Leaf Mobile, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Knight Therapeutics00503.00
Leaf Mobile00203.00

Knight Therapeutics presently has a consensus price target of C$7.88, suggesting a potential upside of 47.20%. Leaf Mobile has a consensus price target of C$0.88, suggesting a potential upside of 103.49%. Given Leaf Mobile's higher possible upside, analysts plainly believe Leaf Mobile is more favorable than Knight Therapeutics.

Summary

Knight Therapeutics beats Leaf Mobile on 5 of the 7 factors compared between the two stocks.

Aurora Cannabis (TSE:ACB) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Aurora Cannabis and Knight Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora CannabisN/AN/AN/A
Knight TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Aurora Cannabis and Knight Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$285.54 million5.75C$-3,829,329,160.00C($19.34)-0.43
Knight TherapeuticsC$199.52 million3.45C$41.08 millionC$0.3216.77

Knight Therapeutics has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Aurora Cannabis and Knight Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis44001.50
Knight Therapeutics00503.00

Aurora Cannabis presently has a consensus price target of C$9.79, suggesting a potential upside of 18.13%. Knight Therapeutics has a consensus price target of C$7.88, suggesting a potential upside of 47.20%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Knight Therapeutics is more favorable than Aurora Cannabis.

Summary

Knight Therapeutics beats Aurora Cannabis on 6 of the 8 factors compared between the two stocks.

HEXO (TSE:HEXO) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Valuation and Earnings

This table compares HEXO and Knight Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HEXOC$111.62 million8.11C$-247,381,320.00C($2.02)-3.66
Knight TherapeuticsC$199.52 million3.45C$41.08 millionC$0.3216.77

Knight Therapeutics has higher revenue and earnings than HEXO. HEXO is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for HEXO and Knight Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HEXO02012.67
Knight Therapeutics00503.00

HEXO presently has a consensus price target of C$1.79, indicating a potential downside of 75.79%. Knight Therapeutics has a consensus price target of C$7.88, indicating a potential upside of 47.20%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Knight Therapeutics is more favorable than HEXO.

Profitability

This table compares HEXO and Knight Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HEXON/AN/AN/A
Knight TherapeuticsN/AN/AN/A

Summary

Knight Therapeutics beats HEXO on 7 of the 9 factors compared between the two stocks.

Knight Therapeutics (TSE:GUD) and OrganiGram (TSE:OGI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Knight Therapeutics and OrganiGram's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Knight TherapeuticsN/AN/AN/A
OrganiGramN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Knight Therapeutics and OrganiGram, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Knight Therapeutics00503.00
OrganiGram34201.89

Knight Therapeutics presently has a consensus price target of C$7.88, suggesting a potential upside of 47.20%. OrganiGram has a consensus price target of C$3.78, suggesting a potential upside of 28.47%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Knight Therapeutics is more favorable than OrganiGram.

Earnings & Valuation

This table compares Knight Therapeutics and OrganiGram's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$199.52 million3.45C$41.08 millionC$0.3216.77
OrganiGramC$72.40 million12.11C$-340,283,853.00C($1.14)-2.58

Knight Therapeutics has higher revenue and earnings than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Knight Therapeutics beats OrganiGram on 7 of the 8 factors compared between the two stocks.

HLS Therapeutics (TSE:HLS) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Valuation and Earnings

This table compares HLS Therapeutics and Knight Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$56.53 million9.70C$-24,566,584.00C($0.77)-22.32
Knight TherapeuticsC$199.52 million3.45C$41.08 millionC$0.3216.77

Knight Therapeutics has higher revenue and earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for HLS Therapeutics and Knight Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HLS Therapeutics00213.33
Knight Therapeutics00503.00

HLS Therapeutics presently has a consensus price target of C$30.50, suggesting a potential upside of 77.02%. Knight Therapeutics has a consensus price target of C$7.88, suggesting a potential upside of 47.20%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe HLS Therapeutics is more favorable than Knight Therapeutics.

Profitability

This table compares HLS Therapeutics and Knight Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HLS TherapeuticsN/AN/AN/A
Knight TherapeuticsN/AN/AN/A

Summary

Knight Therapeutics beats HLS Therapeutics on 5 of the 9 factors compared between the two stocks.

ICC Labs (CVE:ICC) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, analyst recommendations and valuation.

Valuation and Earnings

This table compares ICC Labs and Knight Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICC LabsC$533,684.00419.04C$2.35 millionC$0.0295.29
Knight TherapeuticsC$199.52 million3.45C$41.08 millionC$0.3216.77

Knight Therapeutics has higher revenue and earnings than ICC Labs. Knight Therapeutics is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ICC Labs and Knight Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICC Labs0000N/A
Knight Therapeutics00503.00

Knight Therapeutics has a consensus price target of C$7.88, suggesting a potential upside of 47.20%. Given Knight Therapeutics' higher probable upside, analysts clearly believe Knight Therapeutics is more favorable than ICC Labs.

Profitability

This table compares ICC Labs and Knight Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICC LabsN/AN/AN/A
Knight TherapeuticsN/AN/AN/A

Summary

Knight Therapeutics beats ICC Labs on 5 of the 7 factors compared between the two stocks.


Knight Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Leaf Mobile logo
LEAF
Leaf Mobile
1.2$0.43+9.3%C$2.47 billionC$31.09 million-18.70
Aurora Cannabis logo
ACB
Aurora Cannabis
1.2$8.29+7.7%C$1.64 billionC$285.54 million-0.43Analyst Downgrade
News Coverage
Gap Down
HEXO logo
HEXO
HEXO
0.7$7.39+3.9%C$905.02 millionC$111.62 million-3.66Gap Up
OrganiGram logo
OGI
OrganiGram
1.4$2.94+0.7%C$876.81 millionC$72.40 million-2.58Analyst Upgrade
HLS Therapeutics logo
HLS
HLS Therapeutics
1.4$17.23+1.0%C$548.29 millionC$56.53 million-22.32Gap Up
ICC
ICC Labs
0.5$1.62+6.2%C$228.24 millionC$533,684.0095.29Gap Up
FIRE
The Supreme Cannabis
1.3$0.30+0.0%C$216.73 millionC$49.44 million-1.41News Coverage
The Green Organic Dutchman logo
TGOD
The Green Organic Dutchman
0.8$0.30+3.4%C$155.52 millionC$21.50 million-0.60News Coverage
EPI
ESSA Pharma
0.6$8.20+6.7%C$145.78 millionN/A-8.27
WMD
WeedMD
1.3$0.28+3.6%C$95.35 millionC$27.21 million-3.13
NINE
Delta 9 Cannabis
1.1$1.03+2.9%C$89.36 millionC$12.87 million19.07Gap Up
FLWR
The Flowr
1.0$0.25+2.0%C$70.01 millionC$7.51 million-0.26Gap Up
Acerus Pharmaceuticals logo
ASP
Acerus Pharmaceuticals
0.5$0.05+22.2%C$69.19 millionC$1.09 million-1.25News Coverage
Gap Down
RX
BioSyent
0.8$7.58+0.3%C$64.81 millionC$22.33 million26.14
Cipher Pharmaceuticals logo
CPH
Cipher Pharmaceuticals
0.7$1.41+13.5%C$43.16 millionC$21.61 million7.01News Coverage
Gap Down
MDP
Medexus Pharmaceuticals
0.6$7.12+1.7%C$38.66 millionC$108.29 million-3.93
VIR
Viridium Pacific Group
0.7$0.38+5.3%C$37.54 millionC$1.09 million-2.97Gap Up
ZOM
Zomedica Pharmaceuticals Corp. (ZOM.V)
0.6$0.29+7.0%C$36.73 millionN/A-2.61Gap Down
IN
InMed Pharmaceuticals
0.6$4.19+1.7%C$33.73 millionN/A-2.40
NDVA
Indiva
1.3$0.43+3.5%C$27.54 millionC$7.92 million-3.32
Harvest One Cannabis logo
HVT
Harvest One Cannabis
0.4$0.09+0.0%C$21.51 millionC$8.50 million-0.24News Coverage
EVE
Eve & Co Incorporated
1.0$0.26+0.0%C$21.32 millionC$2.84 million-0.80News Coverage
SUGR
SugarBud Craft Growers
0.7$0.05+0.0%C$11.81 millionC$66,906.00-0.03
NU
NeutriSci International
0.5$0.17+8.8%C$8.65 millionC$74,572.00-12.14
AQS
Aequus Pharmaceuticals
0.9$0.15+0.0%C$6.03 millionC$2.59 million-13.64
LBL
Lattice Biologics
0.5$0.04+0.0%C$4.67 millionC$2.24 million-2.22
THCX
(THCX.V)
0.6$5.30+6.2%C$0.00N/A0.00High Trading Volume
News Coverage
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Up
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Up
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00News Coverage
Gap Up
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5N/AN/AC$0.00N/A0.00
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00News Coverage
Gap Up
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.